Novo Nordisk vs. Genentech
Patent litigation relating to human growth hormone and insulin settled out of court, the companies announce June 29. Novo and Genentech will cross-license certain patents relating to human growth hormone. Beginning at the end of August, Novo will also receive a worldwide license under Genentech patents relating to insulin and Genentech will receive payments from Novo
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth